Neuronano AB was founded in 2006 and is part of the Cimon group. The company is conducting a research project that aims to discover and build on groundbreaking new treatments for Parkinson’s disease.
Neuronano AB has taken a step towards the commercial development of a product for Deep Brain Stimulation (DBS) targeted at Parkinson’s disease.
The challenge is to invent, patent, develop, and commercialise a new generation of innovative electrodes for implantation and stimulation deep within the brain. Super-thin electrodes combined with careful and innovative positioning have the potential to give Parkinson’s sufferers a whole new quality of life free from their symptoms and pain.
Design for optimal treatment
Parkinson’s disease is a neurological disorder where the nerve cells that produce the neurotransmitter dopamine slowly disappear. Dopamine is important for the brain’s control of body movements, which means that the disease impairs body control. Common symptoms include shaking, slowness, and stiffness. The disease occurs gradually, which means sufferers may have the disease for several years without knowing it. Parkinson’s disease cannot be diagnosed until clear symptoms have arisen.
Although there is no cure for Parkinson’s, there are several treatment options that alleviate symptoms and improve quality of life. These commonly include dopamine-regulating drugs and, in more severe cases, treatment using DBS, which is electrical stimulation via electrodes in the brain.
What makes the Neuronano electrodes unique is the combination of materials, size, flexibility, and innovative design. The ultra-thin electrodes are positioned in clusters, which are then cast into a gelatine carrier for insertion into the brain (DBS probe). The advantage of the gelatine embedding of the electrode cluster is that it minimises damage during implantation and reduces side effects. In addition, the innovative design of the cluster with ultra-thin electrodes allows for optimal stimulation, which results in the increased specificity of the treatment.
We’ve been involved in the project for several years here at Avalon Innovation, providing project management of product development and conducting design work for various prototypes of the DBS product. This is an incredibly exciting project that we hope will change the lives of many people in the future.
For more information, please contact:
+46 (0)70 723 28 42